Squamous cell carcinoma of the head and neck (SCCHN) research hub

A Phase II, Randomized, Double-Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck

This study looks at new treatments for a type of head and neck cancer. It compares two drug combinations to see if they help shrink tumors and improve how long people live, while also checking for side effects.